Abstract: A lyophilized pharmaceutical composition of hydrolytically unstable pharmaceutical compounds, such as phenobarbital or salts thereof, is provided. An aqueous solution for injection of phenobarbital or salts thereof that is reconstituted from the lyophilized pharmaceutical composition is provided. The pharmaceutical compositions of the present disclosure have an ethanol content in the range from about 5000 ppm to about 70000 ppm. The composition of the present disclosure, in certain embodiments, is stable following two years of storage, wherein the total impurities do not exceed 0.5%. The pharmaceutical compositions of the present disclosure may be used for the treatment of neonatal seizures.

Abstract: The present invention relates to a lyophilized pharmaceutical composition of hydrolytically unstable pharmaceutical compounds, such as phenobarbital or salts thereof. The present invention also relates to an aqueous solution for injection of phenobarbital or salts thereof that is reconstituted from the lyophilized pharmaceutical composition. The pharmaceutical compositions of the present disclosure have an ethanol content in the range from about 5000 ppm to about 70000 ppm. The composition of the present disclosure, in certain embodiments, is stable following two years of storage, wherein the total impurities do not exceed 0.5%. The pharmaceutical compositions of the present disclosure may be used for the treatment of neonatal seizures.

Abstract: The present invention relates to a lyophilized pharmaceutical composition of hydrolytically unstable pharmaceutical compounds, such as phenobarbital or salts thereof. The present invention also relates to an aqueous solution for injection of phenobarbital or salts thereof that is reconstituted from the lyophilized pharmaceutical composition. The pharmaceutical compositions of the present disclosure have an ethanol content in the range from about 5000 ppm to about 70000 ppm. The composition of the present disclosure, in certain embodiments, is stable following two years of storage, wherein the total impurities do not exceed 0.5%. The pharmaceutical compositions of the present disclosure may be used for the treatment of neonatal seizures.

Abstract: Systems may anticipate exploitation of cyber threats to various technologies. The systems may receive threat-intelligence data from a threat intelligence source, extracting a technology identified in the threat-intelligence data, and extract a first tactic from the threat-intelligence data wherein the tactic is associated with the technology. The system may receive ground-truth data from a ground-truth data source and extract a second technology identified in the ground-truth data. The first technology may match the second technology. The system may extract a second tactic from the ground-truth data wherein the tactic is associated with the technology with the first tactic matching the second tactic. The system may train a statistical model to predict threats to at least one of the first technology or the second technology.

Abstract: Computer-implemented methods and systems for assessing software vulnerabilities through a combination of external threat intelligence and internal information technology data are disclosed.

Abstract: Embodiments of a computer-implemented system and methods for predicting and/or determining a probability of a cyber-related attack in view of data indicative of hacking discussions are disclosed.

Abstract: Computer-implemented systems and methods are disclosed for learning correlations between D2web activity and historical cryptocurrency trend reversals. The learned correlations are leveraged to generate rules executable by a computing device. When satisfied, the rules are utilized to predict a cryptocurrency price reversal.

Abstract: This invention is directed to a security system for wireless access points which includes a clamp assembly and a locking device. The clamp assembly is clamped around I/O panel connectors, and then secured to the access point enclosure frame via a metal capture plate. The metal capture plate extends from an end of the clamp assembly and engages the lower half of the access point enclosure frame, securing the clamp assembly to the access point. Additionally, the locking device locks the clamp assembly halves in a closed position, thus preventing removal of the access point and blocking any unauthorized users from accessing the I/O ports.